Physician

Kathryn K. Najafi-Tagol, M.D.

According to 2025 Medicare claims, Kathryn Najafi-Tagol, M.D. (NPI: 1184678112) practices ophthalmology in the San Rafael, CA market, with the plurality of this provider's patient population coming from Marin, CA. This provider's primary affiliated billing organization is KATHRYN NAJAFI TAGOL MD A PROFESSIONAL CORPORATION (NPI: 1578198099; TIN: 84-4149764) and primary practice location at 94903-2102.

Najafi-Tagol's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,272 traditional Medicare patients, billed 6,187 HCPCS/CPT codes, and received $479,352 in Medicare payments. The top billing code was 92014 (Established patient complete exam of visual system). Part D data shows 3,528 prescription claims across 760 beneficiaries totaling $453,703 in drug costs, led by Lumigan (Bimatoprost). Open Payments data shows 20 records totaling $1,019. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $262,920 to $453,703. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$273K$545K2015 Medicare payment: $420,918 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $405,653 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $459,409 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $489,634 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $545,435 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $396,173 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $494,314 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $383,062 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $405,430 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $479,352 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20159834,715$420,918
20161,0014,702$405,653
20171,0374,849$459,409
20181,2015,323$489,634
20191,2525,865$545,435
20201,0695,138$396,173
20211,2586,650$494,314
20221,0424,646$383,062
20231,1435,224$405,430
20241,2726,187$479,352

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$227K$454K2015 Drug cost: $262,920 (USD; Tot_Drug_Cst)2016 Drug cost: $294,011 (USD; Tot_Drug_Cst)2017 Drug cost: $346,173 (USD; Tot_Drug_Cst)2018 Drug cost: $390,129 (USD; Tot_Drug_Cst)2019 Drug cost: $378,991 (USD; Tot_Drug_Cst)2020 Drug cost: $328,886 (USD; Tot_Drug_Cst)2021 Drug cost: $369,590 (USD; Tot_Drug_Cst)2022 Drug cost: $379,239 (USD; Tot_Drug_Cst)2023 Drug cost: $429,028 (USD; Tot_Drug_Cst)2024 Drug cost: $453,703 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20154172,294$262,920
20164282,353$294,011
20174912,628$346,173
20185912,724$390,129
20195752,512$378,991
20205352,500$328,886
20216152,934$369,590
20226392,939$379,239
20237003,244$429,028
20247603,528$453,703

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
92014Established patient complete exam of visual system482570$121
92083Exam of visual field with extended testing873985$63
92134Imaging of retina439478$39
92250Photography of the retina482489$36
92133Imaging of optic nerve778794$33

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
LumiganBimatoprost1067,483$76,375
XiidraLifitegrast502,340$53,711
RestasisCyclosporine652,610$50,713
RhopressaNetarsudil Mesylate633,498$39,705
Brimonidine TartrateBrimonidine Tartrate34821,613$37,748

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.20$1,019Carl Zeiss Meditec USA, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Kathryn K. Najafi-Tagol, M.D.?

Tedicare shows public-source Medicare data for Kathryn K. Najafi-Tagol, M.D. (NPI 1184678112), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kathryn K. Najafi-Tagol, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kathryn K. Najafi-Tagol, M.D.?

Kathryn K. Najafi-Tagol, M.D. is linked to KATHRYN NAJAFI TAGOL MD A PROFESSIONAL CORPORATION (billing NPI 1578198099) in the available physician profile data.

Does Kathryn K. Najafi-Tagol, M.D. have Open Payments data?

Kathryn K. Najafi-Tagol, M.D. has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.